Many studies have examined the etiology of fever complicating neutropenia. Little is known about the etiology of fever occurring immediately following recovery from myelosuppression. We reviewed 165 episodes of fever in patients who were admitted to the University of Pennsylvania Medical Center (philadelphia) between 1 August 1992 and 15 August 1994 for the treatment of acute leukemia. We included patients who had episodes of fever (temperature of
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Many studies have examined the etiology of fever complicating neutropenia. Little is known about the etiology of fever occurring immediately following recovery from myelosuppression. We reviewed 165 episodes of fever in patients who were admitted to the University of Pennsylvania Medical Center (philadelphia) between 1 August 1992 and 15 August 1994 for the treatment of acute leukemia. We included patients who had episodes of fever (temperature of ;;:;:38°C) for ;;:;:48 hours within 10 days after an absolute neutrophil count of :::::;;500 cellslmm 3 was determined. Twenty-nine (20%) of 145 episodes met these criteria. In 5 (17%) of 29 episodes the cause of fever was a bacterial infection, in 6 (21%) of 29 episodes the cause of fever was noninfectious, and in 12 (41%) of 29 episodes the cause of fever was unknown. Six (21%) of 29 episodes were due to documented or suspected fungal infection, four were due to suspected pulmonary aspergillosis, and two were due to systemic candidal infections. Fever following recovery from chemotherapy-induced neutropenia is common. Fungal infections occur frequently after recovery from myelosuppression despite widespread use of empirical and prophylactic antifungal therapy. Improved strategies for diagnosing and preventing fungal infections in patients who have fever following recovery from myelosuppression are clearly needed.
Many studies have examined the etiology offever complicating neutropenia induced by chemotherapy for the treatment of leukemia [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . Little attention has been focused on the relatively common occurrence of fever in the leukemic patient that occurs immediately following recovery from myelosuppression. Talbot et a1. identified this phenomenon in 15% of a cohort of patients with acute leukemia who received chemotherapy from 1 January 1983 to 31 December 1986 [11] . In 35% of these episodes, fungal infection was the cause of fever after recovery from chemotherapy-induced neutropenia.
In the decade following the study by Talbot et aI., there have been several changes in practice that might be expected to impact on both the incidence and etiology of fever after bone marrow recovery. These changes include the universal initiation ofempirical antifungal therapy after several days ofneutropenic fever despite the use of broad-spectrum antibiotics, the increasing use of prophylactic antiviral and antifungal therapy, the use of granulocyte colony-stimulating factor (G-CSF), and changes in the broad-spectrum antibiotic regimens used for fever in patients with neutropenia.
We therefore retrospectively reviewed the records of all patients with acute leukemia who received chemotherapy at the University of Pennsylvania Medical Center between 1 August 1992 and 15 August 1994 to determine whether recent changes in the management of neutropenic fever have resulted in alterations in the prevalence and etiologies of fever following bone marrow recovery. We also attempted to identify risk factors for the development of fever following bone marrow recovery and to examine the yield of various diagnostic methods.
Patients and Methods
We retrospectively reviewed the medical records of all patients who received chemotherapy for the treatment of acute nonlymphocytic leukemia, acute lymphocytic leukemia, or chronic myelogenous leukemia in blast crisis at the University of Pennsylvania Medical Center between 1 August 1992 and 15 August 1994. Fever was defined as an oral temperature of ;;;:;: 38°C that persisted for a minimum of 48 hours. All patients who met these criteria within 10 days following the resolution of chemotherapy-induced neutropenia were included in the study. Neutropenia was defined as an absolute neutrophil count of~500 cells/mm 3 • We included patients who were admitted to the hospital after a recent discharge following chemotherapy as well as patients who received outpatient chemotherapy.
To assign a cause of the fever, both the inpatient chart and any pertinent outpatient records were thoroughly reviewed in each case. The diagnoses favored in the inpatient chart were given the heaviest weight, as were separate notes that had been kept by the infectious disease consultant for many of the cases. Pneumonia was defined as the presence of new pulmonary infiltrates on a chest radiograph that were concurrent with fever and either cough or shortness of breath. Bloodstream infection was established by growth of the same bacteria in at least both bottles of one set of blood cultures. A drug reaction was established on the basis of fever and rash that was associated with negative cultures and with resolution of symptoms following withdrawal of the identified drug. Sepsis was defined as fever plus hypotension.
To determine whether patients with serious infectious complications could be distinguished from those without these diagnoses, the two groups were analyzed for the following variables: leukemic diagnosis; type of chemotherapy; duration of neutropenia; duration and pattern (constant vs. intermittent) of fever associated with neutropenia and fever that occurred after neutropenia resolved; use of antibacterial, antiviral, and antifungal agents for prophylaxis or empirical therapy; and use of G-CSF.
To assess the effectiveness of the diagnostic and therapeutic strategies used, a record was made of the imaging and laboratory studies performed and of their usefulness in establishing a diagnosis. Statistical analyses were performed with use of the X 2 test.
Results
During the 2-year study period, 165 patients were admitted to the University of Pennsylvania Medical Center to receive chemotherapy for acute leukemia. Twenty of these patients had neutrophil counts of >500/mm 3 , leaving 145 admitted patients eligible for review in this study. Of 145 patients who were admitted, 29 (20%) met the entry criteria and comprise the study population. Table 1 summarizes the demographics, clinical course, and outcome of these 27 patients (patients 6 and 13 were admitted twice). The patients were neutropenic for a mean of 23 days (range, 2-82 days). In 26 of the 29 episodes, patients experienced neutropenic fever for an average of 13 days. Appropriate empirical antibiotic therapy was administered during all episodes, for a mean of 83% of the neutropenic period. Empirical amphotericin B therapy was given during 21 (72%) episodes at a mean of 4 days after the first neutropenic fever. G-CSF was given during 20 (69%) episodes of neutropenia. After recovery from neutropenia, patients were febrile for an average of 5 days. Ten (34%) of these 29 episodes were new fevers (i.e., the patient was afebrile for the preceding 48 hours). Three (10%) of the 29 episodes of fever following bone marrow recovery resulted in the death of the patient. Only one death was attributed to an infection; in that case the patient had sepsis due to vancomycin-resistant enterococci.
In five (17%) of 29 episodes, bacterial infection was documented as the primary cause of persistent fever. Three of these infections were discovered after resolution of neutropenia, whereas two persisted from the neutropenic period. In three of these cases, Enterococcus species was one of the isolated pathogens. Patient 8 died as a result of overwhelming sepsis due to vancomycin-resistant enterococci. Three (10%) patients (nos. 7, 9, and 10) had persistent bacteremia that responded to removal of the Hickman catheter and antibiotic treatment.
In six (21 %) of 29 episodes the cause of fever was noninfectious. Drug reaction was the suspected cause of fever in three (10%) of 29 episodes. All three of these patients had fevers for at least 7 days following resolution of neutropenia. Each patient had a rash. In addition, patient 13 had a severe outbreak of oral herpes simplex that probably contributed to her fevers. In all three cases, the patient's fevers responded to drug withdrawal, although fever persisted for several days after this intervention in each case. Other noninfectious causes of fever included phlebitis (two patients) and relapsed tumor burden (one patient; this patient [no.17] died as a result).
No cause was established for persistent fever in 12 (41 %) of 29 cases. In all cases the fever eventually resolved; in three cases it resolved without antibiotic therapy, in three cases with empirical antibiotic therapy only, in one case with empirical amphotericin B therapy, and in five cases with both empirical antibiotic therapy and amphotericin B.
In six (21 %) of the 29 episodes, a fungal infection was diagnosed either microbiologically (two cases) or clinically (four cases). Pulmonary aspergillosis was suspected to be the cause of four of these episodes (patients 1-4). Unfortunately, the cause of these episodes could not be histologically confirmed because of severe thrombocytopenia. All four patients had received a course of empirical amphotericin B therapy during neutropenia. All four patients responded clinically and radiographically to an increased dosage of amphotericin B (1-1.5 mg/[kg . d]) after a mean of 4 days. These patients continued to receive amphotericin B therapy for a minimum total dose of I g.
Two patients had systemic candidal infections. After patient 5 received > I g of amphotericin B when his temperature was at its nadir, his condition was diagnosed as disseminated candidiasis. An abdominal CT scan demonstrated multiple nodules in this patient's spleen, but a definitive diagnosis could not be made on the basis of examination of specimens obtained by splenic biopsies performed with a laparoscope. A liver biopsy was performed because the liver function tests were markedly elevated, but examination of biopsy specimens did not reveal any abnormalities. The patient's fevers resolved abruptly after splenectomy. Pathologic examination of splenic specimens revealed multiple fungal forms consistent with Candida specimens, but the results of all cultures remained negative. Culture of blood from the patient with episode 6 yielded C. albicans for several days.
This patient had not previously received empirical amphotericin B therapy. The patient had both a clinical and a microbiological response to amphotericin B therapy and removal of the central venous catheter.
Several potential risk factors for the development of fungal infection following bone marrow recovery were investigated, but none was identified as statistically significant. These risk factors included the following: gender; age; induction, remission, or relapse status of leukemia; type of leukemia; type of chemotherapy; duration of neutropenia; duration and pattern em 1996; 22 (June) NOTE. ALL = acute lymphocytic leukemia; AML = acute myelogenous leukemia; ANC = absolute neutrophil count; BMT = bone marrow transplant. * Nadir = ANC of~500/mm3.
of fever associated with neutropenia and fever that occurred after neutropenia resolved; antifungal prophylaxis with fluconazole; treatment with total parenteral nutrition; duration of broad-spectrum antibiotic therapy during neutropenia; duration of empirical amphotericin B therapy; treatment with G-CSF;
and elevations in levels of transaminases, total bilirubin, or alkaline phosphatase during or following neutropenia (P > .05, data not shown). Many diagnostic tests were perfonned during the evaluation of the etiology of fever after bone marrow recovery. A total of 140 blood cultures were performed for 29 patients. Thirteen (9%) of these cultures were positive, and only three (10%) of these patients had at least one positive blood culture. In each of these three cases, the initial set of blood cultures obtained after marrow recovery was positive. Culture of urine had a low yield in the absence of symptoms of urinary tract infection, as none of the 27 urine cultures performed for 16 patients was positive.
Discussion
Fever after recovery from chemotherapy-induced neutropenia remains a common event and occurs in 20% of patients treated for acute leukemia. Changes in practice during the past decade have included widespread and early administration of empirical amphotericin B therapy for neutropenic fever, the administration of G-CSF therapy, the use of fluconazole and acyclovir as prophylaxis, and changes in empirical antibiotic regimens; these changes have not impacted the incidence of fever after bone marrow recovery, which occurred in 15% of a cohort of patients from January 1983 through December 1986 [11] that was similar to our own.
Similarly, the incidence of fever episodes that are caused by fungal infection has decreased slightly, although probably not significantly. In the series of cases reported by Talbot et al. [11] ,35% of fever episodes were attributed to fungal infection. Fungal infection was diagnosed in 21 % of our patients despite the use of empirical amphotericin B therapy for neutropenic fever in five of the six patients who developed a fungal infection. Of note, the incidence of drug reactions was similar in the present series (10%) and in the series of cases reported by Talbot et al. (12%), as was the incidence of viral infections (3% vs. 8%, respectively) and catheter-related bacteremias (10% vs. 8%, respectively). Intraabdominal and perirectal abscesses were more common in the series of cases reported by Talbot et al. (23%) than in the current series (0).
Many more patients had an unknown cause of fever in the present study (41 %) than in the study reported by Talbot et al. in 1988 (12%) . It is possible that this increase in fever with an unknown cause correlates with the decrease in the number of documented fungal infections and that empirical amphotericin B therapy suppresses some fungal infections to a subclinical level.
The present study is limited by the small sample size and the fact that the analysis was done retrospectively and with a historical control group, leading to the potential for bias in reporting the etiology offever. In addition, most ofthe episodes of fever attributed to fungal infection were suspected on the basis of radiographic and clinical findings and were not documented microbiologically. The difficulty of documenting fungal infections premortem in this setting has been well described [12] .
The lack of a significant decrease in the incidence of fungal infection in our study was disappointing given the prompt initiation of empirical antifungal therapy. Other investigators have noted that aspergillosis often develops in patients with acute leukemia who are receiving amphotericin B therapy [12, 13] . The dose of empirical amphotericin B that we currently use is 0.5 -0.8 mg/(kg' d), a dose that would be expected to be effective against most Candida species but that is ineffective against Aspergillus species. It is of interest that 33% of fungal infections following bone marrow recovery in our series were due to Candida species whereas 50% of fungal infections in a previously described large cohort of patients who had not recovered from myelosuppression were due to these organisms. Conversely, 67% of fungal infections in our series were due to Aspergillus species compared with 30% in the previously described cohort. These findings suggest that early empirical amphotericin B therapy and/or prophylaxis with fluconazole has decreased the incidence of candidemia but is ineffective in preventing or treating aspergillosis.
Despite a high incidence of fungal infections, no patient in our series died of a fungal infection. This fact is likely due to prompt recognition and treatment of suspected fungal infection rather than early empirical antifungal therapy during neutropenic fever.
Many conditions must be considered in the differential diagnosis of patients with fever following bone marrow recovery, but our study points to several principles of diagnosis and management. Fungal and bacterial infections should be at the top of the list of differential diagnoses because of their associated morbidity and mortality. In cases in which these infections are suspected, blood cultures should be performed, a chest roentgenogram should be taken, and a thorough physical examination should be performed with particular attention to the lungs and site of an indwelling catheter. Further blood cultures should be performed sparingly, as their yield in cases in which the initial cultures were negative is low.
The possibility of a drug reaction should also be investigated, but it is important to remember that the cause of fever for a sizeable number of patients will not be identified and that these patients will defervesce and do well. However, in cases in which the course of fever is protracted and no cause of fever has been identified, performing a CT or MRI study of the abdomen to search for visceral fungal infection should be considered.
Several important questions remain unanswered regarding the optimal prevention of fungal infections in patients with fever following bone marrow recovery. It is unclear whether most of the fungal infections are present during neutropenia but manifest themselves only during marrow recovery or whether the fungal infections arise de novo after recovery from granulocytopenia. The former seems likely, suggesting that improved diagnostic strategies, prophylaxis, and/or empirical therapy might be helpful in lowering the rate of fungal infection in patients undergoing chemotherapy for acute leukemia. Larger studies need to be done to identify patients at the highest risk for the development of fungal infection. The roles of alter-native antifungal agents, combination therapies, and higher dose empirical antifungal therapy should be investigated as well.
